knowledge -WSS

knowledge

author：explore 2025-09-27 11:32:37 - browse：2871

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Fetal surgery at risk from Dobbs and new abortion restrictions

WSS

Leading voice in opioid treatment defends methadone clinic system

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Gene editing the human germline: What are the risks?

FDA investigates CAR

Orchard's therapy for neuron disease in children wins FDA approval

UnitedHealth’s Optum accused of antitrust violations in California

focus

knowledge

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Colonoscopy prep: Liquid

As demand for Covid shots wanes, Moderna seeks its next success

U.K. researchers warn about biases in medical devices, algorithms

Novavax promises a turnaround & Lilly roils the obesity market

CVS Caremark has created a new ploy: the drug ‘rebate credit’

How to save PrEP access — and even expand it

Nurses recount patients attacks

Supreme Court strikes down use of affirmative action

Flagship Pioneering launches a new biotech in two countries

focus

UnitedHealth’s Optum accused of antitrust violations in California

Creating egg and sperm cells from stem cells raises ethical issues

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

AstraZeneca to buy developer of next

Takeda, Janssen join wearable maker to measure scratching

Argenx readies a blockbuster opportunity with drug for autoimmune disease

leisure time

focus

explore

hotspot